Short answer
Mineralys Therapeutics, Inc. (MLYS) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$39M
- +6.8% YoY
- EPS (diluted)
- −$0.47
- +40.5% YoY
Source: XBRL data from the Mineralys Therapeutics, Inc. (MLYS) Q1 2026 10-Q on SEC EDGAR. USD.
Mineralys Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales generated
- Net loss $39.3M vs $42.2M YoY; net loss margin not applicable without revenue
- R&D expense $24.4M vs $37.9M; G&A expense $21.0M vs $6.6M
- Cash, equivalents, investments $646.1M; ATM proceeds $20.2M from 568,320 shares
- Cash expected to fund operations at least twelve months; FDA PDUFA target December 22, 2026
Risk Factors
- No material changes to risk factors since 2025 Form 10-K
- Carried-forward risks include adverse effects on business, financial condition, results, and stock price
- Affiliate trading risk: Catalys Pacific Fund adopted a plan to sell 2,000,000 common shares
- Trading-plan overhang: sales scheduled from May 9, 2026 through March 31, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mineralys Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.